Antidepressant dosage form

Abstract

The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.

1 . A dosage form for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol having controlled release properties, the dosage form comprising:
 (a) a wall comprising at least in part a composition permeable to the passage of fluid, but not to 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol, which wall surrounds;   (b) a compartment comprising a first layer and a second layer;   (c) a drug composition in the first layer of the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol and a hydroxypropylalkylcellulose wherein said alkyl is of 1 to 7 carbons;   (d) a displacement composition in the second layer of the compartment comprising an osmotically active compound; and   (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form.   
     
     
         2 . The dosage form of  claim 1 , wherein said hydroxypropylalkylcellulose comprises hydroxypropylmethylcellulose. 
     
     
         3 . The dosage form of  claim 1 , wherein the drug composition weighs about 25% more than the displacement composition. 
     
     
         4 . A dosage form for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol having controlled release properties, the dosage form comprising:
 (a) a wall comprising at least in part a composition permeable to the passage of fluid, but not to 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol, which wall surrounds;   (b) a compartment comprising a first layer and a second layer;   (c) a drug composition in the first layer of the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol and poly(ethylene oxide);   (d) a displacement composition in the second layer of the compartment comprising an osmotically active compound and poly(ethylene oxide); and   (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form.   
     
     
         5 . The dosage form of  claim 1 , further comprising an external coat on the exterior of the wall that provides instant release of a drug for instant therapy, comprising a drug composition comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol. 
     
     
         6 . The dosage form of  claim 4 , further comprising an external coat on the exterior of the wall that provides instant release of a drug for instant therapy, comprising a drug composition comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol. 
     
     
         7 . A dosage form for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol having controlled release properties, the dosage form comprising:
 (a) a wall comprising at least in part a composition permeable to the passage of fluid, but not to 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol, which wall surrounds;   (b) a compartment comprising a first layer and a second layer;   (c) a drug composition in the first layer of the compartment comprising 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol and a hydroxyalkylcellulose wherein said alkyl is of 1 to 6 carbons;   (d) a displacement composition in the second layer of the compartment comprising an osmotically active compound; and   (e) an exit passageway in the dosage form for delivering the drug composition from the dosage form.   
     
     
         8 . A dosage form for delivering 0.5 mg to 750 mg of 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol over an extended period of time wherein said dosage form comprises a hydroxypropylalkylcellulose wherein said alkyl is of 1 to 7 carbons or a hydroxyalkylcellulose wherein said alkyl is of 1 to 6 carbons. 
     
     
         9 . The dosage form of  claim 8 , wherein said extended period of time is at least 15 hours. 
     
     
         10 . The dosage form of  claim 8 , wherein said extended period of time is at least 16 hours. 
     
     
         11 . The dosage form of  claim 8 , wherein said extended period of time is at least 20 hours. 
     
     
         12 . The dosage form of  claim 8  wherein said dosage form comprises a hydroxypropylalkylcellulose wherein said alkyl is of 1 to 7 carbons. 
     
     
         13 . The dosage form of  claim 12  wherein said hydroxypropylalkylcellulose is a hydroxypropylmethylcellulose. 
     
     
         14 . The dosage form of  claim 13  further comprising an osmotically active compound selected from the group consisting of salts, oxides, esters, carbohydrates and acids. 
     
     
         15 . The dosage form of  claim 14  wherein said osmotically active compound is a salt selected from the group consisting of magnesium sulfate, magnesium chloride, sodium chloride, lithium chloride, potassium chloride, potassium sulfate, sodium sulfate, sodium sulfite, lithium sulfate, ammonium chloride, potassium lactate, magnesium succinate. 
     
     
         16 . The dosage form of  claim 15  wherein said salt is sodium chloride. 
     
     
         17 . The dosage form of  claim 8  comprising a hydroxyalkylcellulose wherein said alkyl is of 1 to 6 carbons. 
     
     
         18 . The dosage form of  claim 17 , wherein said hydroxyalkylcellulose is hydroxypropylcellulose. 
     
     
         19 . The dosage form of  claim 17  further comprising an osmotically active compound selected from the group consisting of salts, oxides, esters, carbohydrates and acids. 
     
     
         20 . The dosage form of  claim 19  wherein said osmotically active compound is a salt selected from the group consisting of magnesium sulfate, magnesium chloride, sodium chloride, lithium chloride, potassium chloride, potassium sulfate, sodium sulfate, sodium sulfite, lithium sulfate, ammonium chloride, potassium lactate, magnesium succinate. 
     
     
         21 . The dosage form of  claim 20  wherein said salt is sodium chloride. 
     
     
         22 . A dosage form for delivering 0.5 mg to 750 mg of 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol over an extended period of time wherein said dosage form comprises a hydroxypropylmethylcellulose. 
     
     
         23 . The dosage form of  claim 22 , wherein said extended period of time is at least 15 hours. 
     
     
         24 . The dosage form of  claim 22 , wherein said extended period of time is at least 16 hours. 
     
     
         25 . The dosage form of  claim 22 , wherein said extended period of time is at least 20 hours. 
     
     
         26 . The dosage form of  claim 22  further comprising an osmotically active compound selected from the group consisting of salts, oxides, esters, carbohydrates and acids. 
     
     
         27 . The dosage form of  claim 26  wherein said osmotically active compound is a salt selected from the group consisting of magnesium sulfate, magnesium chloride, sodium chloride, lithium chloride, potassium chloride, potassium sulfate, sodium sulfate, sodium sulfite, lithium sulfate, ammonium chloride, potassium lactate, magnesium succinate. 
     
     
         28 . The dosage form of  claim 27  wherein said salt is sodium chloride.